/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Expected eligibility for PCSK9i therapy in secondary prevention, ESC/EAS guidelines vs Irish reimbursement criteria in post PCI patients
Event: ESC Congress 2023
Topic: Drug therapy
Session: Risk factors and prevention: lipids (3)
Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention
Event: ESC Congress 2023
Topic: Drug therapy
Session: Risk factors and prevention: lipids (2)
